Try our Advanced Search for more refined results
Health
-
April 01, 2026
NJ Hospital Workers Win Collective Cert. In OT, Break Suit
A New Jersey healthcare network must face overtime claims on a collective basis, a federal judge ruled, saying a former employee adequately backed up allegations that the network had companywide policies under which it automatically deducted time for meal breaks that weren't taken and left bonuses out of overtime calculations.
-
April 01, 2026
Sentara Health Strikes $1.5M Deal In Stable Value Fund Suit
Virginia-based healthcare system Sentara Health will pay $1.5 million to settle a class action claiming it failed to remove an underperforming investment fund from its employee retirement plan, according to federal court filings.
-
April 01, 2026
Mass. Cannabis Businesses Say Repeal Bid Misleads Voters
A coalition of Massachusetts cannabis business owners Wednesday challenged the constitutionality of a proposal to repeal retail marijuana legalization at the ballot box this November.
-
April 01, 2026
PBM Opioid Crisis Suit Stays In Federal Court, Judge Says
A Michigan federal judge on Tuesday denied a request from the state attorney general to remand to state court a suit accusing two pharmacy benefit managers of fueling the opioid crisis, saying the case will remain in federal court because work performed for federal and nonfederal clients cannot be separated.
-
April 01, 2026
CFO Scores $867K Win In Health Device Co. Wage Suit
A wearable health device company must pay its former chief financial officer nearly $867,000 after a Connecticut federal jury determined it stiffed him on his full wages and benefits, according to court filings.
-
April 01, 2026
Mangione's NY Trial Moved Hours After SDNY Schedule Tweak
A New York state court judge said Wednesday that Luigi Mangione's trial for the alleged murder of UnitedHealthcare CEO Brian Thompson would begin Sept. 8, moving the date hours after a Manhattan federal judge said the federal trial against him would commence in late October.
-
March 31, 2026
State Privacy Enforcers Broadening Work As Resources Grow
Privacy regulators from California, Connecticut and two other states said Tuesday that their behind-the-scenes enforcement work will soon yield public actions that focus not only on established topics such as consumer opt-outs and transparency, but also fresh issues like harms stemming from artificial intelligence and ensuring fines are more than just "a cost of doing business."
-
March 31, 2026
'Best Judicial System In The World': Alsup Reflects On Career
Before taking inactive status late last year, U.S. District Judge William H. Alsup presided over historic litigation in California's Northern District for 26 years, arriving at his San Francisco chambers every weekday before dawn to prepare for the day's work.
-
March 31, 2026
Split 4th Circ. Affirms Injunction On W.Va. Drug Discount Law
A split Fourth Circuit panel sided with a trio of pharmaceutical manufacturers Tuesday that opposed a West Virginia law addressing drug delivery in the 340B program, saying the law attempted to reshape the "contractual bargain" Congress makes with private parties through its spending powers.
-
March 31, 2026
Novartis Seeks To Block New Wash. 340B Drug-Pricing Law
Novartis has called on a Washington federal judge to block a new state law it claims illegally expands the subsidies manufacturers must pay under the federal government's 340B Drug Pricing Program, arguing drugmakers will lose millions of dollars annually if the law is allowed to take effect in June.
-
March 31, 2026
Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks
Novartis must face a False Claims Act suit alleging it improperly had doctors prescribe its multiple sclerosis drug, a New York federal judge said Monday, finding the relator plausibly pled scienter by bringing evidence that the company "kept meticulous track" of how many prescriptions doctors wrote for the drug.
-
March 31, 2026
5th Circ. Grills Fraudsters Over $158M Healthcare Scheme
A Fifth Circuit panel pushed back on two men's contention that their convictions in a $158 million healthcare scheme should get thrown out, asking Tuesday how the evidence the jury heard wasn't enough to uphold the convictions.
-
March 31, 2026
Anesthesia Parent Can't Duck Antitrust Suit, But Affiliate Can
The parent company of U.S. Anesthesia Partners Inc. remains in the crosshairs of a private antitrust suit accusing it of trying to monopolize Texas anesthesia services, while a federal judge dismissed for now claims against an affiliate that he said was too far removed from the alleged rollup strategy.
-
March 31, 2026
Goodwin-Led Whoop Raises $575M At $10B Valuation
Wearable technology company Whoop Inc. announced Tuesday that it hit a $10.1 billion valuation after wrapping its latest funding round led by Goodwin Procter LLP, securing $575 million in investor commitments.
-
March 31, 2026
Full Fed. Circ. Is Told Panel Defied EcoFactor In DePuy Case
DePuy Synthes is urging the full Federal Circuit to review a circuit panel's decision reviving patent infringement litigation against it, saying the panel majority undermined the court's en banc EcoFactor decision on when to admit expert testimony.
-
March 31, 2026
SEIU Arbitration Suit Strains Order, Hospital Says
A Service Employees International Union unit is stretching an arbitrator's finding that a hospital unfairly punished a worker who tested positive for cannabis use by seeking to restrict drug tests going forward, the hospital argued Tuesday in its bid to beat an Ohio federal suit.
-
March 31, 2026
Telemedicine Biz Can't Escape Investor Suit Over User Losses
A New York federal judge on Tuesday ruled Teladoc Health Inc. cannot escape an investor suit over its declining user base and increased advertising budget, saying the departure of its former chief executive in 2024 could indicate the company knew it was misleading shareholders about its financial state.
-
March 31, 2026
Ill. Panel Says No Error In Doc's Nerve Damage Suit Win
An Illinois state appeals court panel won't upset a jury verdict that cleared a gynecologist from claims alleging her medical negligence caused nerve damage during a long procedure, finding the trial court wasn't wrong in its evidentiary or jury decisions.
-
March 31, 2026
Big Insurers Must Face 'Repricing' Antitrust Claims
Major insurance companies including Aetna, Cigna, Humana and UnitedHealth must face claims they conspired to reduce reimbursements to healthcare providers, a Massachusetts federal judge ruled Monday, finding that the doctors' allegations could constitute antitrust violations.
-
March 31, 2026
Mich. Judge OKs Bias Training For Healthcare Workers
A Michigan judge has upheld a state requirement that healthcare professionals undergo implicit bias training to obtain or renew their licenses, finding the mandate was within the state licensing bureau's power.
-
March 31, 2026
Biogen Paying $5.6B For Apellis As 4 Firms Advise
Biogen Inc. said Tuesday that it has agreed to acquire Apellis Pharmaceuticals Inc. in a cash transaction valued at about $5.6 billion, with four law firms steering the transaction focused on key therapies for kidney and eye disorders.
-
March 31, 2026
Pot Opponents Seek To Block CMS Hemp Benefit Program
A coalition of anti-cannabis activists is suing federal health regulators to block a program designed to reimburse Medicare beneficiaries for the use of federally legal hemp products that have small amounts of THC.
-
March 31, 2026
Insurer Says Yale Was 'Misleading' In $4.1M Transplant Claim
A Liberty Mutual unit accused Yale University's health system of making "serious and material misstatements" about a plan member's bone marrow transplant, the insurer said in its answer and counterclaim for a declaratory judgment that it can continue to deny the $4.1 million claim.
-
March 31, 2026
Kirkland, Goodwin Steer Lilly $7.8B 'Sleep-Wake' Disorder Deal
Pharmaceutical giant Eli Lilly & Co., advised by Kirkland & Ellis LLP, announced plans Tuesday to acquire daytime sleepiness-focused pharmaceutical company Centessa Pharmaceuticals PLC, led by Goodwin Procter LLP, in a deal worth up to $7.8 billion.
-
March 31, 2026
Nurses Union Can't Force Arbitration, Mich. Hospital Says
A Michigan hospital has urged a federal court to toss a lawsuit alleging it is refusing to arbitrate claims that it removed more than $500,000 in retirement health account credits owed to registered nurses, arguing the dispute falls outside the terms of its collective bargaining agreement with the nurses union bringing the claims.
Expert Analysis
-
5 Different AI Systems Raise Distinct Privilege Issues
A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.
-
Health Co.'s 'Success Story' Misstep Holds HIPAA Lessons
Cadia Healthcare Facilities' fall settlement with the U.S. Department of Health and Human Services for improperly disclosing patients' protected health information in online success stories is an instructive example of Health Insurance Portability and Accountability Act risks that can arise from digital marketing efforts, say attorneys at Woods Rogers.
-
Opinion
AI-Assisted Arbitration Needs Safeguards To Ensure Fairness
As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.
-
Trans Care Enforcement Landscape Is Evolving Quickly
The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.
-
Series
Playing Piano Makes Me A Better Lawyer
Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.
-
11th Circ. May Bring Tectonic Shift To FCA Qui Tam Actions
The Eleventh Circuit's upcoming decision in Zafirov v. Florida Medical Associates, assessing whether the False Claims Act permits ordinary citizens to stand as officers of the federal government, could significantly limit private relators' ability to bring FCA actions, say attorneys at Saul Ewing.
-
AI-Generated Doc Ruling Guides Attys On Privilege Risks
A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.
-
To Survive FCA Actions, Small Cos. Must Take Offensive Steps
A fumbled response to False Claims Act allegations can doom lower-middle-market businesses, and with FCA enforcement hitting record levels for two years, smaller companies must have offensive strategies ready that focus their limited resources on defeating civil qui tam and federal criminal actions, says Derrelle Janey at Olshan Frome.
-
The Law Firm Merger Diaries: Leadership Strategy After Day 1
For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.
-
How US Liability Law Is Becoming The Primary Regulator Of AI
Comprehensive federal AI regulation remains fragmented and uncertain — but U.S. courts, applying long-standing doctrines of liability and responsibility, are actively shaping how AI systems are designed, deployed and governed, and companies are aligning their AI practices because courts may hold them accountable if they do not, says Alexander Lima at Wesco International.
-
Record FCA Recoveries Signal Intensified Healthcare Focus
In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.
-
Fed. Circ. In Jan.: On The Validity Of Expert Testimony
The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.
-
Methods For Challenging State Civil Investigative Demands
Ongoing challenges to enforcement actions underscore the uphill battle businesses face in arguing that a state investigation is prohibited by federal law, but when properly deployed, these arguments present a viable strategy to resist civil investigative demands issued by state attorneys general, say attorneys at Troutman Pepper.
-
Calif.'s Civility Push Shows Why Professionalism Is Vital
The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.
-
A Potential Shift In FDA's Approach To Drug Trial Design
Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.